LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Overlap Found for Ovarian Cancer Subtypes and Endometriosis

By LabMedica International staff writers
Posted on 22 Mar 2022
Print article
Image: Genetic Overlap Found for Ovarian Cancer Subtypes and Endometriosis (Photo courtesy of University of Queensland)
Image: Genetic Overlap Found for Ovarian Cancer Subtypes and Endometriosis (Photo courtesy of University of Queensland)

Endometriosis is a chronic gynecological disease affecting up to 12% of reproductive-age women. The disease is characterized by the presence of endometriotic lesions outside the uterus and is associated with pelvic pain and subfertility.

Ovarian cancer is the deadliest gynecologic cancer. Fewer than 50% of women survive beyond five years after diagnosis due to the rapid development of chemoresistance and the absence of effective early detection strategies. Recent genome-wide association studies (GWASs) have provided strong evidence for a genetic contribution to risk of both endometriosis and epithelial ovarian cancer (EOC).

Molecular Bioscientists at the University of Queensland (Brisbane, Australia) and their colleagues estimated the genetic correlation and evaluate the causal relationship between genetic liability to endometriosis and EOC histotypes, and identify shared susceptibility loci. They started with more than two dozen SNPs linked to endometriosis through a prior genome-wide association study meta-analysis involving hundreds of thousands of endometriosis cases, EOC cases, or unaffected controls. The investigators identified genetic risk loci linked to both endometriosis and several forms of EOC, particularly clear cell ovarian cancer and endometrioid ovarian cancer. Cases from the high-grade serous ovarian cancer subtype, on the other hand, showed more tenuous genetic ties to endometriosis risk.

Nine genes were associated at genome-wide significance with endometriosis (GREB1, MIR4429, KDR, WNT4, SYNE1, CDKN2B-AS1, CDC42, ID4, PTPRO), 67 with high-grade serous ovarian cancer (HGSOC), one with low-grade serous (LGSOC) (KIAA1024), four for low malignant serous (LMPSOC) (TERT, SLC6A18, MIR4457, CLPTM1L), and 27 for mucinous (MOC) in single-trait gene-based analysis. Genome-wide significant genes for endometriosis were nominally significant for clear cell (CCOC) (GREB1, MIR4429, and WNT4), endometrioid (ENOC) (CDNK2B-AS1), and HGSOC (CDNK2B-AS1, MIR4429, and WNT4).

Both endometriosis and clear cell ovarian cancer involved variants on chromosomes 1, 2, 4, 5, 6, 7, 8, 9, 12, and 17, for example, while high-grade serous ovarian cancer risk was associated with several endometriosis risk loci on chromosomes 2, 9, 10, and 18 that did not appear to be linked to risk of clear cell ovarian cancer or endometrioid ovarian cancer histotypes. Of the 28 loci associated with both endometriosis and EOC, for example, the team highlighted 19 sites containing SNPs that were independently linked to both endometriosis and EOC via the same candidate variants.

The investigators incorporated additional chromatin immunoprecipitation sequence, DNA methylation, endometrial cell single-cell RNA sequence, and other data for subsequent analyses looking at everything from the causal variants, genes, and pathways involved to the functional mechanisms that may play a role in tissues and cell types impacted by endometriosis and EOC.

Sally Mortlock, PhD, a Molecular Bioscientist and first author of the study, said, “We found that individuals carrying certain genetic markers that predispose them to having endometriosis also have a higher risk of certain epithelial ovarian cancer subtypes, namely clear cell and endometrioid ovarian cancer.”

The authors concluded that they had found evidence of a strong genetic correlation and causal relationship between endometriosis and two EOC histotypes, CCOC and ENOC, and to a lesser extent with HGSOC. Further investigation into shared genomic regions revealed different genetic variants, genes, and pathways that likely contribute to the causal relationship with the different histotypes. The study was published on March 15, 2022 in the journal Cell Reports Medicine.

Related Links:
University of Queensland 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.